Can Cagrilintide Cause Heart Palpitations?

What Cagrilintide Is and How It Works

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, designed to be used in combination with the GLP-1 receptor agonist semaglutide in a formulation known as CagriSema. Amylin is a hormone naturally co-secreted alongside insulin from the pancreas, and it plays a meaningful role in regulating satiety, slowing gastric emptying, and supporting glucose control after meals.

Unlike GLP-1 receptor agonists, which bind to receptors on the gut and brain to reduce appetite, cagrilintide acts on amylin receptors found in the brainstem and peripheral tissues. These are distinct but overlapping pathways, and combining them appears to produce greater weight loss than either mechanism alone. This dual action also means the drug's physiological footprint extends across multiple systems, including pathways that intersect with cardiovascular regulation.

Because cagrilintide is still advancing through late-stage clinical trials and does not yet have standalone regulatory approval, much of what is known about its side effect profile comes from trial data rather than post-market surveillance.

Heart Palpitations and Why Weight Loss Drugs Can Trigger Them

Palpitations are sensations of a racing, fluttering, or pounding heartbeat. They can feel alarming but are not always clinically dangerous. Common triggers include changes in the autonomic nervous system, dehydration, electrolyte imbalances, caffeine, anxiety, and medications that influence heart rate or rhythm.

Weight loss drugs as a category have a complicated relationship with heart rhythm. Rapid caloric restriction, particularly in the early weeks of treatment, can alter cardiac preload and electrolyte balance. Gastrointestinal side effects like nausea, vomiting, and reduced food intake can compound this by causing fluid and mineral losses. Changes in sympathetic nervous system tone, which regulate the body's fight-or-flight response and directly influence heart rate, are also plausible contributors.

Not every palpitation requires intervention. Frequency, duration, and accompanying symptoms are what determine clinical significance. A brief fluttering sensation during the first week of dose escalation is a very different concern than a sustained rapid heartbeat accompanied by chest tightness or lightheadedness.

What Clinical Trial Data Reveals

Data from the REDEFINE and SCALE clinical trial programs provides the most detailed picture currently available of cagrilintide's cardiovascular effects. These trials show modest heart rate increases in the range of 1 to 3 beats per minute with cagrilintide-containing regimens. This is broadly similar to what is observed with semaglutide alone and is consistent with the known class effect of both amylin-based and GLP-1-based therapies.

Palpitations have appeared in early-phase trial adverse event reports, but they are not listed among the most common side effects documented in published data. The signal is present but relatively modest compared to the well-characterized gastrointestinal effects such as nausea and vomiting.

The table below compares the cardiovascular profiles of three prominent weight loss agents based on available clinical data:

This comparison highlights that small heart rate increases are a class-wide pattern rather than a cagrilintide-specific concern.

Why Some Patients Report Palpitations on Cagrilintide

Several mechanisms may explain why individual patients experience palpitations while taking cagrilintide, even if the drug's direct cardiovascular effect appears modest.

First, nausea and vomiting are common during dose escalation and can lead to meaningful dehydration and losses of potassium and magnesium. Both electrolytes are critical to maintaining stable heart rhythm, and their depletion is a well-established trigger for palpitations.

Second, rapid early weight loss itself can alter the heart's filling dynamics. As blood volume and body composition shift, some patients experience benign arrhythmic sensations that do not reflect structural cardiac disease but are real and noticeable.

Third, amylin receptors in the brainstem may influence autonomic tone, which in turn affects heart rate variability. This mechanism is plausible based on the location of receptor expression, though it is not yet fully characterized in human trial data.

Understanding the likely cause of a patient's palpitations helps clinicians distinguish between a physiological adjustment that will resolve versus a pattern that merits further evaluation.

Who Faces Higher Risk and What Warning Signs Demand Attention

Certain patients carry a higher baseline risk for cardiac side effects from any weight loss medication. Those with pre-existing arrhythmias, untreated or undertreated thyroid disorders, a history of atrial fibrillation, or known electrolyte abnormalities should discuss these conditions explicitly with a prescribing clinician before starting cagrilintide. Patients with a history of long QT syndrome face particular consideration, as any drug-mediated heart rate change or electrolyte disruption can carry greater consequence.

Red-flag symptoms that warrant stopping the medication and seeking immediate care include palpitations accompanied by chest pain, pressure, or tightness; episodes of fainting or near-fainting; shortness of breath at rest; or any palpitation episode lasting more than a few minutes without resolution. These presentations require evaluation before resuming treatment.

Mild, brief palpitations that resolve quickly and occur in isolation without other symptoms are a clinically different scenario. They still deserve reporting to a prescriber but do not necessarily indicate a dangerous process.

Managing and Monitoring Palpitations During Treatment

For patients beginning cagrilintide, several practical steps can reduce palpitation risk during the dose escalation period. Maintaining consistent hydration throughout the day and prioritizing dietary sources of potassium and magnesium, or discussing supplementation with a clinician, addresses one of the most modifiable risk factors.

For patients with any cardiac history, a baseline ECG before starting therapy is a reasonable precaution that provides a reference point if symptoms arise later. This is not universally required but may be suggested based on individual risk.

Once symptoms appear, timely reporting to a clinician matters. Doctronic, the first AI legally authorized to practice medicine, offers 24/7 access to consultations that can help patients decide whether their palpitation pattern warrants urgent evaluation or a more measured monitoring approach. Prompt communication with a provider allows for dose adjustments, additional testing, or reassurance, whichever is appropriate, before a manageable issue becomes a more complex one.

The Bottom Line

Cagrilintide can be associated with heart palpitations through both direct and indirect pathways. Clinically, small heart rate increases are a known class effect of amylin and GLP-1 based therapies, and cagrilintide does not appear to significantly raise this risk beyond what is seen with semaglutide alone. Indirect contributors such as nausea-related dehydration and electrolyte shifts are likely behind many patient reports. For most people, the risk appears low and manageable with adequate hydration and electrolyte monitoring. Patients with existing cardiac conditions require a more careful, proactive approach before and during treatment. Doctronic, with over 22 million AI consultations completed and 99.2% treatment plan alignment with board-certified physicians, offers free 24/7 AI consultations to help you evaluate your cardiovascular risk profile before starting cagrilintide. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.